SCHEMBL15769401

SCHEMBL15769401

Cc1ccc(Nc2ncc(Cl)c(N(C)[C@H]3CCCN4CCCC[C@H]34)n2)cc1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.38
JAK1 P23458 5/20 0.38
AXL P30530 2/20 0.38
WEE1 P30291 1/20 0.38
SIGMAR1 Q99720 3/20 0.38
LCK P06239 1/20 0.38
JAK3 P52333 1/20 0.38
PAK1 Q13153 1/20 0.37
CDK4 P11802 3/20 0.36
CCND1 P24385 3/20 0.36
CCNA2 P20248 2/20 0.36
CDK2 P24941 2/20 0.36
CDK1 P06493 2/20 0.36
PIK3CD O00329 1/20 0.36
PRKAB2 O43741 1/20 0.36
NUAK1 O60285 1/20 0.36
CCNT1 O60563 1/20 0.36
ABL1 P00519 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15769548 0.92 CDK1 (0.40) JAK2WEE1LCKJAK3CDK4
SCHEMBL15770097 0.92 JAK3 (0.45) JAK2AXLWEE1SIGMAR1LCK
SCHEMBL15769778 0.90 JAK2 (0.39) JAK2JAK1AXLWEE1SIGMAR1
SCHEMBL15769875 0.90 JAK2 (0.39) JAK2JAK1AXLWEE1SIGMAR1
SCHEMBL15769772 0.90 GRM5 (0.39) AXLWEE1LCKJAK3PAK1
SCHEMBL15770094 0.90 JAK3 (0.38) AXLWEE1SIGMAR1LCKJAK3
SCHEMBL15769749 0.88 JAK3 (0.48) LCKJAK3
SCHEMBL15769154 0.88 CDK1 (0.41) LCKJAK3CDK4CCND1CCNA2
SCHEMBL15770162 0.85 SYK (0.42) JAK2JAK1SIGMAR1
SCHEMBL15769468 0.84 JAK3 (0.45) JAK2AXLWEE1SIGMAR1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP claimed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US claimed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US claimed
EP-2928891-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2019-02-20 EP disclosed
US-9913843-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2018-03-13 US disclosed
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2015-10-29 US disclosed
US-9062068-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-06-23 US disclosed
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163022-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB JAK2 337/4885JAK1 565/4885AXL 3738/4885
US-20150306100-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB JAK2 337/4885JAK1 565/4885AXL 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.